Search hospitals > Florida > Jacksonville
Jacksonville Center for Clinical Research
Claim this profileJacksonville, Florida 32216
Global Leader in Heart Failure
Global Leader in Cardiovascular Disease
Conducts research for Alzheimer's Disease
Conducts research for Obesity
Conducts research for Diabetes Mellitus
255 reported clinical trials
5 medical researchers
Summary
Jacksonville Center for Clinical Research is a medical facility located in Jacksonville, Florida. This center is recognized for care of Heart Failure, Cardiovascular Disease, Alzheimer's Disease, Obesity, Diabetes Mellitus and other specialties. Jacksonville Center for Clinical Research is involved with conducting 255 clinical trials across 285 conditions. There are 5 research doctors associated with this hospital, such as Michael Koren, Steven Toenjes, William Namen II, DPM, and Erin Moore, MD.Top PIs
Michael KorenJacksonville Center for Clinical Research4 years of reported clinical research
Studies Heart Failure
Studies Congestive Heart Failure
6 reported clinical trials
7 drugs studied
Steven ToenjesJacksonville Center for Clinical Research2 years of reported clinical research
Studies Alzheimer's Disease
Studies Mild Cognitive Impairment
5 reported clinical trials
5 drugs studied
William Namen II, DPMRiver City Clinical Research12 years of reported clinical research
Studies Ulcer
Studies Prevention of Diabetic Foot
1 reported clinical trial
2 drugs studied
Erin Moore, MDJacksonville Center for Clinical Research3 years of reported clinical research
Studies Aortic Aneurysm
Studies Abdominal Aortic Aneurysm
1 reported clinical trial
2 drugs studied
Clinical Trials running at Jacksonville Center for Clinical Research
Obesity
Heart Failure
Gout
Cardiovascular Disease
Alzheimer's Disease
Cerebral Amyloid Angiopathy
High Cholesterol
Coronavirus
Diabetes Mellitus
Abdominal Aortic Aneurysm
Maridebart Cafraglutide
for Obesity
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Recruiting1 award Phase 32 criteria
Revita DMR
for Obesity
Fractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both a midpoint analysis and a pivotal analysis. Patients who previously lost at least 15% of their body weight on a GLP-1 can qualify for the open label REVEAL-1 cohort. The data generated from the REVEAL-1 cohort will be used for open label reporting as the study progresses. The REMAIN-1 randomized cohort will enroll patients living with obesity and a body mass index ("BMI") between 30 and 45 kg/m2 who are not currently on a GLP-1 drug. Patients will be prescribed tirzepatide and titrated to achieve at least 15% total body weight loss, at which time tirzepatide will be discontinued and patients will be randomized to Revita versus sham at 2:1. Midpoint Analysis of Randomized Cohort: The midpoint analysis of the randomized cohort will be performed at three months of follow-up on approximately 45 patients, allowing us to assess and report on safety and efficacy signals that could be anticipated in the pivotal analysis. These patients are distinct from those included in the pivotal analysis. Pivotal Analysis of Randomized Cohort: The pivotal analysis of the randomized cohort will be performed on approximately 315 patients (distinct from those included in the midpoint analysis) and will evaluate safety and efficacy in the first co-primary endpoint, which is weight regain from the time of tirzepatide discontinuation in Revita DMR versus sham patients at six months, with a primary objective of demonstrating a benefit of Revita DMR versus sham for weight maintenance after GLP-1 discontinuation. The second co-primary endpoint evaluates a responder rate among the Revita DMR treated group at one year to demonstrate the durability of the Revita DMR procedure for weight maintenance after discontinuation of a GLP-1-based therapy. Secondary objectives will include evaluation of the effectiveness of the Revita DMR procedure on the change in blood glucose levels, cardiovascular disease ("CVD") risk factors, body composition and pre-diabetes status. All patients enrolled in the study will receive diet and lifestyle counseling.
Recruiting0 awards N/A4 criteria
PF-07081532 + Rybelsus
for Type 2 Diabetes and PF-07081532
This trial is testing a new drug called PF-07081532 to see if it can help people lose weight or control their blood sugar. The study includes obese individuals without diabetes and diabetic patients already taking metformin. Participants will receive either the new drug or an approved treatment and will be monitored over time.
Recruiting0 awards Phase 24 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Jacksonville Center for Clinical Research?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.